Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 134

1.

HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.

Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, Loutfy M, Trottier S, Smaill F, Yudin MH, Klein M, Harris M, Cohen J, Wobeser W, Bitnun A, Lapointe N, Samson L, Brophy J, Karatzios C, Ogilvie G, Coutlée F, Raboud J; HPV in HIV Study Group.

Vaccine. 2016 Aug 17. pii: S0264-410X(16)30673-9. doi: 10.1016/j.vaccine.2016.08.016. [Epub ahead of print]

PMID:
27544584
2.

Establishing the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS): Operationalizing Community-based Research in a Large National Quantitative Study.

Loutfy M, Greene S, Kennedy VL, Lewis J, Thomas-Pavanel J, Conway T, de Pokomandy A, O'Brien N, Carter A, Tharao W, Nicholson V, Beaver K, Dubuc D, Gahagan J, Proulx-Boucher K, Hogg RS, Kaida A; CHIWOS Research Team.

BMC Med Res Methodol. 2016 Aug 19;16(1):101. doi: 10.1186/s12874-016-0190-7.

3.

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.

Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team.

PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016.

4.

In HIV-1, immediate vs deferred antiretroviral therapy and isoniazid vs no isoniazid reduced severe illness at 30 mo.

Smaill F.

Ann Intern Med. 2015 Dec 15;163(12):JC5. doi: 10.7326/ACPJC-2015-163-12-005. No abstract available.

PMID:
26666807
5.

In early HIV infection, immediate vs deferred antiretroviral therapy reduced serious illnesses at 3 years.

Smaill F.

Ann Intern Med. 2015 Dec 15;163(12):JC4. doi: 10.7326/ACPJC-2015-163-12-004. No abstract available.

PMID:
26666806
6.

Sexual inactivity and sexual satisfaction among women living with HIV in Canada in the context of growing social, legal and public health surveillance.

Kaida A, Carter A, de Pokomandy A, Patterson S, Proulx-Boucher K, Nohpal A, Sereda P, Colley G, O'Brien N, Thomas-Pavanel J, Beaver K, Nicholson VJ, Tharao W, Fernet M, Otis J, Hogg RS, Loutfy M; CHIWOS Research Team.

J Int AIDS Soc. 2015 Dec 1;18(Suppl 5):20284. doi: 10.7448/IAS.18.6.20284. eCollection 2015.

7.

Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003-2011.

Shigayeva A, Rudnick W, Green K, Tyrrell G, Demczuk WH, Gold WL, Gubbay J, Jamieson F, Plevneshi A, Pong-Porter S, Richardson S, McGeer A; Toronto Invasive Bacterial Diseases Network.

Vaccine. 2016 Feb 3;34(6):846-53. doi: 10.1016/j.vaccine.2015.11.021. Epub 2015 Nov 18.

PMID:
26602266
8.

Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.

Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, Johnstone J, Kitai I, Krajden S, Lovinsky R, Muller M, Powis J, Rau N, Walmsley S, Tyrrell G, Bitnun A, McGeer A; Toronto Invasive Bacterial Diseases Network.

Clin Infect Dis. 2016 Jan 15;62(2):139-47. doi: 10.1093/cid/civ803. Epub 2015 Sep 9.

PMID:
26354970
9.

Antibiotics for asymptomatic bacteriuria in pregnancy.

Smaill FM, Vazquez JC.

Cochrane Database Syst Rev. 2015 Aug 7;(8):CD000490. doi: 10.1002/14651858.CD000490.pub3. Review.

PMID:
26252501
10.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

11.

The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study.

Klein MB, Young J, Dunn D, Ledergerber B, Sabin C, Cozzi-Lepri A, Dabis F, Harrigan R, Tan DH, Walmsley S, Gill J, Cooper C, Scherrer AU, Mocroft A, Hogg RS, Smaill F; Canadian−European Clade Collaboration.

CMAJ Open. 2014 Oct 1;2(4):E318-29. doi: 10.9778/cmajo.20140017. eCollection 2014 Oct.

12.

Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section.

Smaill FM, Grivell RM.

Cochrane Database Syst Rev. 2014 Oct 28;(10):CD007482. doi: 10.1002/14651858.CD007482.pub3. Review.

PMID:
25350672
13.

Breaking the Glass Ceiling: Increasing the Meaningful Involvement of Women Living With HIV/AIDS (MIWA) in the Design and Delivery of HIV/AIDS Services.

Carter A, Greene S, Nicholson V, O'Brien N, Sanchez M, de Pokomandy A, Loutfy M, Kaida A; Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS) Research Team.

Health Care Women Int. 2015;36(8):936-64. doi: 10.1080/07399332.2014.954703. Epub 2014 Nov 20.

PMID:
25256222
14.

New approaches to TB vaccination.

Xing Z, Jeyanathan M, Smaill F.

Chest. 2014 Sep;146(3):804-12. doi: 10.1378/chest.14-0439.

PMID:
25180725
15.

Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future?

Smaill F, Xing Z.

Expert Rev Vaccines. 2014 Aug;13(8):927-30. doi: 10.1586/14760584.2014.929947. Epub 2014 Jun 17.

PMID:
24935214
16.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

17.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

18.

Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions.

Rodrigues-Coutlée C, Archambault J, Money D, Ramanakumar AV, Raboud J, Hankins C, Koushik A, Richardson H, Brassard P, Franco EL, Coutlée F; Canadian Women's HIV Study Group.

J Clin Virol. 2013 Dec;58(4):660-5. doi: 10.1016/j.jcv.2013.10.015. Epub 2013 Oct 17.

PMID:
24210329
19.

The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada.

Kennedy VL, Serghides L, Raboud JM, Su D, Blitz S, Hart TA, Walmsley SL, Angel JB, Smaill FM, Ralph ED, Tharao WE, Loutfy MR; Ontario HIV Fertility Research Team.

AIDS Care. 2014;26(6):777-84. doi: 10.1080/09540121.2013.855295. Epub 2013 Nov 9.

PMID:
24206065
20.

Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.

Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, Devlin R, Downey J, Katz K, Kitai I, Krajden S, Ostrowska K, Richardson D, Richardson S, Sarabia A, Silverman M, Simor AE, Tyrrell G, McGeer A; Toronto Invasive Bacterial Diseases Network.

Vaccine. 2013 Dec 2;31(49):5863-71. doi: 10.1016/j.vaccine.2013.09.049. Epub 2013 Oct 5.

PMID:
24099873
Items per page

Supplemental Content

Loading ...
Write to the Help Desk